Əsas səhifə

Çap

Əks əlaqə

İnfo
Galactomannan in the diagnosis of invasive aspergillosis in immunocompromized patients

Mündəricat

Galactomannan in the diagnosis of invasive aspergillosis in immunocompromized patients

Sübutlu məlumatların xülasələri
16.07.2017 • Sonuncu dəyişiklik 16.07.2017
Editors

At the cut-off value 0.5 ODI (Optical Density Index), galactomannan detection in serum by ELISA test for the diagnosis of invasive aspergillosis seems to have a sensitivity of 78% and a specificity of 81%. At the cut-off value 1.5, the specificity would rise to 95% at the cost of sensitivity (64%).

A Cochrane review included 54 studies (50 in the meta-analyses), containing 5660 patients, of whom 586 had proven or probable invasive aspergillosis. When using an optical density index (ODI) of 0.5 as a cut-off value, the sensitivity of the test was 82% (73% to 90%) and the specificity was 81% (72% to 90%). At a cut-off value of 1.0 ODI, the sensitivity was 72% (65% to 80%) and the specificity was 88% (84% to 92%). At a cut-off value of 1.5 ODI, the sensitivity was 61% (47% to 75%) and the specificity was 93% (89% to 97%). None of the potential sources of heterogeneity had a statistically significant effect on either sensitivity or specificity.

At the cut-off value 0.5 ODI in a population of 100 patients with an overall median disease prevalence of 8%, 2 patients who have IA will be missed and 17 patients will be treated or further referred unnecessarily. At the cut-off value 1.5 the figures would be 3 and 5, respectively. The role of the galactomannan detection test in clinical decision making remains unclear.

Comment: The quality of evidence is downgraded by inconsistency (variability in results across studies).

Ədəbiyyat

  1. Leeflang MM, Debets-Ossenkopp YJ, Wang J et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev 2015;(12):CD007394.